BEAM

23.12

3.47% -0.83

Dopo l'orario di chiusura: 23.86 0.74 +3.20%

Beam Therapeutics Inc (BEAM)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché BEAM Giù? Forum Previsione

Precedente Chiudi:

$23.95

Aprire:

$24.4

Volume 24 ore:

5.32M

Relative Volume:

2.84

Capitalizzazione di mercato:

$2.35B

Reddito:

$139.74M

Utile/perdita netta:

$-79.99M

Rapporto P/E:

-22.76

EPS:

-1.0157

Flusso di cassa netto:

$-360.05M

1 W Prestazione:

-8.69%

1M Prestazione:

-21.92%

6M Prestazione:

+0.13%

1 anno Prestazione:

-0.43%

Intervallo 1D:

$23.07

$25.34

Intervallo di 1 settimana:

$23.07

$25.98

Portata 52W:

$13.53

$36.44

Beam Therapeutics Inc Stock (BEAM) Company Profile

Nome

Beam Therapeutics Inc

Settore

Healthcare (1114)

Industria

Biotechnology (623)

Telefono

857-327-8775

Indirizzo

26 LANDSDOWNE STREET, CAMBRIDGE, MA

Dipendente

511

Cinguettio

Prossima data di guadagno

2024-11-05

Ultimi documenti SEC

BEAM's Discussions on Twitter

Compare BEAM vs VRTX, REGN, ALNY, ARGX, INSM

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
BEAM Beam Therapeutics Inc	23.12	2.44B	139.74M	-79.99M	-360.05M	-1.0157
VRTX Vertex Pharmaceuticals Inc	454.97	113.96B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	749.47	78.41B	14.34B	4.50B	3.77B	41.56
ALNY Alnylam Pharmaceuticals Inc	328.70	40.85B	3.71B	313.75M	465.38M	2.2571
ARGX Argen X Se Adr	697.05	42.05B	4.16B	1.29B	734.26M	19.58
INSM Insmed Inc	148.31	29.99B	606.42M	-1.28B	-997.58M	-6.403

Beam Therapeutics Inc Stock (BEAM) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2026-02-20	Iniziato	Canaccord Genuity	Buy
2025-10-09	Iniziato	Jefferies	Buy
2025-03-28	Aggiornamento	BofA Securities	Neutral → Buy
2025-03-10	Aggiornamento	Scotiabank	Sector Perform → Sector Outperform
2025-01-29	Aggiornamento	Cantor Fitzgerald	Neutral → Overweight
2024-11-06	Aggiornamento	Leerink Partners	Market Perform → Outperform
2024-10-16	Iniziato	Scotiabank	Sector Outperform
2024-07-23	Iniziato	H.C. Wainwright	Buy
2024-01-29	Aggiornamento	JP Morgan	Neutral → Overweight
2023-12-15	Downgrade	BofA Securities	Buy → Neutral
2023-12-08	Downgrade	Jefferies	Buy → Hold
2023-10-20	Downgrade	Cantor Fitzgerald	Overweight → Neutral
2023-10-20	Downgrade	Leerink Partners	Outperform → Market Perform
2023-03-21	Iniziato	Bernstein	Mkt Perform
2023-02-01	Iniziato	Cantor Fitzgerald	Overweight
2022-12-20	Aggiornamento	BMO Capital Markets	Market Perform → Outperform
2022-12-13	Iniziato	Citigroup	Buy
2022-06-17	Iniziato	BMO Capital Markets	Market Perform
2022-04-28	Iniziato	Credit Suisse	Neutral
2022-01-05	Iniziato	Guggenheim	Buy
2021-10-19	Iniziato	SVB Leerink	Outperform
2021-09-24	Ripresa	Stifel	Buy
2021-09-10	Iniziato	BofA Securities	Buy
2021-05-11	Iniziato	Redburn	Buy
2021-05-04	Iniziato	RBC Capital Mkts	Sector Perform
2021-03-01	Downgrade	Barclays	Overweight → Equal Weight
2021-02-16	Iniziato	Wells Fargo	Overweight
2021-01-29	Downgrade	JP Morgan	Overweight → Neutral
2021-01-06	Iniziato	Stifel	Hold
2020-08-05	Iniziato	William Blair	Outperform
2020-03-02	Iniziato	Barclays	Overweight
2020-03-02	Iniziato	JP Morgan	Overweight
2020-03-02	Iniziato	Jefferies	Buy
2020-03-02	Iniziato	Wedbush	Outperform

Mostra tutto

Beam Therapeutics Inc Borsa (BEAM) Ultime notizie

Mar 25, 2026

Beam To Extend Current Trial For Pivotal BEAM-302 Development - Citeline News & Insights

Mar 25, 2026

RBC Capital reiterates Beam Therapeutics stock rating on A1AT data By Investing.com - Investing.com Australia

Mar 25, 2026

Leerink raises Beam Therapeutics stock price target on AATD data - Investing.com

Mar 25, 2026

Beam Therapeutics’ BEAM-302 Hits Protective AAT Levels in AATD; 60 mg Picked for Pivotal in H2 2026 - MarketBeat

Mar 25, 2026

Clear Street reiterates Beam Therapeutics stock rating on AATD data - Investing.com UK

Mar 25, 2026

William Blair reiterates Beam Therapeutics stock rating on positive trial data - Investing.com

Mar 25, 2026

Beam Therapeutics (BEAM) Sees Positive Data, Analyst Reaffirms B - GuruFocus

Mar 25, 2026

RBC Capital reiterates Beam Therapeutics stock rating on A1AT data - Investing.com

Mar 25, 2026

Beam Therapeutics Gains On Clinical Update As Gene Therapy Hits Protective Protein Levels - Benzinga

Mar 25, 2026

Beam Therapeutics Says It Advances BEAM-302 to Pivotal Stage With 60 mg Dose Selection - marketscreener.com

Mar 25, 2026

Why Did BEAM Stock Jump 10% In Pre-Market Today? - Stocktwits

Mar 25, 2026

Beam Therapeutics stock jumps on positive trial data By Investing.com - Investing.com Australia

Mar 25, 2026

BEAM: BEAM-302 at 60 mg delivers durable, functional AAT restoration and strong safety in AATD - TradingView

Mar 25, 2026

Beam Therapeutics Reports Positive Phase 1/2 Trial Results for BEAM-302 in Alpha-1 Antitrypsin Deficiency, Selecting 60 mg as Optimal Dose for Pivotal Development - Quiver Quantitative

Mar 25, 2026

Beam Therapeutics selects 60 mg dose for AATD gene therapy trial - Investing.com

Mar 25, 2026

One gene-editing dose kept patients above protective protein levels - Stock Titan

Mar 25, 2026

Mar 21, 2026

Guidance Update: How does Beam Therapeutics Inc perform in inflationary periodsQuarterly Trade Report & Low Drawdown Trading Strategies - baoquankhu1.vn

Mar 21, 2026

Mar 20, 2026

Beam Therapeutics Inc. (NASDAQ:BEAM) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat

Mar 20, 2026

Mar 19, 2026